Orthocell stock came into the FY 2026 result under pressure, down over the past week even after a modest 30 day gain, as investors weighed a rich valuation for an unprofitable biotech. The headline from this earnings release is not the top line. It is the size of the loss investors are still being asked to carry.
Management reported trailing twelve month revenue of A$11.4m, yet a loss from continuing operations of A$13.9m. For a stock trading on a P/S ratio above both its industry and peer averages, that earnings strain is what the market is now focused on.
Like the science behind Orthocell but uneasy about paying up for a stock that is still loss making? Take a look at the 12 high quality undiscovered gems, which focuses on companies combining stronger fundamentals with more balanced valuations.
FY 2026 Earnings Summary
- Revenue, FY 2026 vs. FY 2025 trailing twelve months (TTM): A$11.41m vs. A$7.55m (higher TTM revenue in FY 2026)
- Net loss from continuing operations, FY 2026 vs. FY 2025 TTM: A$13.91m loss vs. A$8.57m loss (larger TTM loss in FY 2026)
- Basic EPS, FY 2026 vs. FY 2025 TTM: A$0.053 loss per share vs. A$0.038 loss per share (larger TTM loss per share in FY 2026)
Prefer clear visuals instead of scrolling through extensive earnings figures for Orthocell? Get a full picture of how the market is valuing the stock in an easy-to-scan format with our company report for Orthocell.
Orthocell bull case leans on revenue traction
For investors drawn to Orthocell as a platform regenerative medicine story, the revenue line offers the clearest support. Trailing revenue of A$11.41m sits above the A$7.55m level from the prior period, which points to growing commercial activity around products like Striate+ and Remplir. That progress fits a thesis that the company is gradually moving deeper into real world use rather than staying purely clinical. Share price performance has been mixed over 7 and 90 days, yet the modest 30 day gain suggests some investors are still prepared to back that growth angle.
Orthocell bear case focuses on deepening losses
The bearish reading of Orthocell is reinforced by widening losses. The loss from continuing operations increased from A$8.57m to A$13.91m and basic EPS loss moved from A$0.038 to A$0.053. That points to heavier earnings pressure even as revenue improves, which keeps funding and dilution risks firmly in view for a small biotech. Recent share price moves, including a 7 day decline of about 4.5% and a 90 day decline of about 5.7%, suggest the market is not ignoring this strain, even with some near term optimism over the past month.
With Orthocell still loss making and trading on a richer P/S multiple, the key question is how long current cash and funding options can support this path. Check the financial health analysis of Orthocell stock to see whether the balance sheet actually backs this story.
Stay Ahead Of Your Next Move
If the mix of growing revenue and deepening losses at Orthocell has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you are invested, keep your focus on the metrics that matter by using the Portfolio Command Center to cut through noise and surface only key developments on Orthocell and your other holdings. Round this out by tapping into crowd wisdom and different angles on the stock through the Community. By seeing potential catalysts and risks early, you may be able to stay ahead of the market rather than reacting after the fact.
Curious About Smart Alternatives To Orthocell
Fresh breakout ideas rarely stay under the radar for long. Spot momentum, identify quality stocks before the crowd, and react while it matters. Get in early.
- Target dependable cash generators and stress test your portfolio resilience against market swings using the curated list of solid balance sheet and fundamentals stocks (22 results).
- Explore structural growth trends that may still be under the radar for now by tapping into the hand picked 55 AI infrastructure stocks.
- Look for income opportunities that can continue paying you as markets move by scanning the curated 9 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com